Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANT: Neoadjuvant Targeted-Immune Therapy + RFA for Recurrent HCC
NCT05277675Unknown
- Sponsor
- Southwest Health System
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of tislelizumab, sintilimab, lenvatinib and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Southwest Health System. Status: unknown.
02
Drugs
tislelizumabsintilimablenvatinibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05277675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277675.